To further understand the relationship between loss of p16 and decreased expression of the SASP, we used TCGA data from primary tumors of skin cutaneous melanoma (SKCM, n=103), pancreatic adenocarcinoma (PAAD, n=178), colorectal adenocarcinoma (COADREAD, n=622), mesothelioma (MESO, n=87), bladder urothelial carcinoma (BLCA, n=407) and glioblastoma multiforme (GBM, n=153), six tumor types where loss of p16 is frequently observed and has clinical implications [70–77]. This evidence concerns the gene CDKN2A and neoplasm.